Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)
Weeks after $143M megaround, low-profile CinCor looks to vault onto Nasdaq with a Roche castoff
CinCor Pharma made some noise earlier this year after raising $143 million in a Series B in October, thanks to a round led by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
